Sinclair Pharma PLC Additional listing (9549A)

TIDMSPH

RNS Number : 9549A

Sinclair Pharma PLC

30 March 2017

Sinclair Pharma plc

Additional listing

London, 30 March 2017 Sinclair Pharma plc (SPH.L), ("Sinclair" or the "Company") the international aesthetics company, announces that 1,570,510 new ordinary shares of 1p each (the "New Ordinary Shares") have been issued and allotted to Christophe Foucher, former COO, in settlement of his severance package as previously announced on 1 September 2016.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 5 April 2017 and, when issued, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following admission of the New Ordinary Shares, Sinclair will have 503,768,952 ordinary shares of 1p in issue.

This announcement contains inside information. The person responsible for arranging for the release of this announcement on behalf of Sinclair is Alan Olby, Chief Financial Officer.

For further information please contact:

 
 Sinclair Pharma plc    Tel: +44 (0) 
                         20 7467 6920 
 Chris Spooner 
  Alan Olby 
  Andy Crane 
 
 Peel Hunt LLP (NOMAD   Tel: +44 (0) 
  and Joint Broker)      20 7418 8900 
 James Steel 
  Oliver Jackson 
 
  RBC Capital Markets   Tel: +44 (0) 
   (Joint Broker)        20 76534000 
 Marcus Jackson 
  Laura White 
 
 Media enquiries 
 FTI Consulting         Tel: +44 (0) 
                         203 727 1000 
 Ben Atwell 
  Brett Pollard 
 

Notes to Editors:

About Sinclair Pharma plc

Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors. For more information, please visit www.sinclairpharma.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

ALSDMGZFZLNGNZZ

(END) Dow Jones Newswires

March 30, 2017 02:02 ET (06:02 GMT)